This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Swiss pharma will base cardiometabolic drugresearch at the new Allston site. Elsewhere, AskBio advanced a gene therapy and Pfizer hired a scientist well versed in GLP-1 science.
Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drugresearch.
Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. Consequently, an increasing number of academic researchers and companies are entering this field. Molecular Therapy 20 , 1831-1832 (2012). Nature 578 , 229-236 (2020). Ylä-Herttuala S.
You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy. The Power of Drug Repurposing Explore the immense potential of drug repurposing as a strategy for targeting undruggable targets.
Interest in IMIDs has grown rapidly in recent years, largely fueled by the view that IMIDs share common inflammatory pathways, and therefore, there is the possibility that novel therapies that work in one IMID may work in other IMIDs.
The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. In fact, it's one of the most exciting areas in drugresearch today. One approach is to look beyond the traditional drug molecule.
In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drugresearch. What is a Pre-Clinical CRO? The global preclinical CRO market was estimated to be valued at US$5.7 billion in 2022 and is projected to reach US$10.2
The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drugresearch and development. The impact was clear: Between 1983 and 2020, FDA approved 599 orphan drugs. A Lasting Impact.
In 1999, Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) and in 2009, the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Follow us on social media at #MalariaFuture. The EDCTP grant of EUR 21.9
This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. ACTIV was founded last April to accelerate drugresearch that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.
percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution.
who require oxygen therapy due to COVID-19, OR.
You can do a challenge trial with deadly diseases, but you need a “rescue therapy.” There have been deaths in phase 1 medical and drugresearch among healthy participants. We wouldn't do a challenge trial for Ebola, because the disease is extremely severe, and there are currently no licensed treatments or vaccines.
The problems: Although the current regulation stimulated orphan drugresearch, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. High-priced cell and gene therapies are being increasingly developed for rare diseases.
Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments. Today, somewhere on the order of 30 million rodents are used yearly in biomedical research in the U.S.
Biologics have gone from monoclonal antibodies to complex bi- and tri-specific antibodies, as well as antibody-drug conjugates. Cell and gene therapies offer patients the possibility of living a relatively normal lifetime, with potential cures for deadly diseases.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content